Received Oct 24, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 3RE73 | — |
Boostrix was give along with Infanrix; This non-serious case was reported by a nurse via call center representative and described the occurrence of overdose in a 11-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number 3RE73, expiry date 16-NOV-2026) for prophylaxis. Concomitant products included Diphtheria vaccine toxoid, Pertussis vaccine acellular 3-component, Tetanus vaccine toxoid (Infanrix). On 07-OCT-2025, the patient received Boostrix. On 07-OCT-2025, an unknown time after receiving Boostrix, the patient experienced overdose (Verbatim: Boostrix was give along with Infanrix). The outcome of the overdose was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 08-OCT-2025 A Nurse Practitioner (NP) reported that a patient received both Boostrix and Infanrix on the same day. The vaccines were administered yesterday to an 11-year-old patient. The nurse practitioner inquired about the safety of administering these two vaccines concurrently.
Infanrix